SCHEMBL21241928

SCHEMBL21241928

Nc1ccc(C(=O)NCC(=O)Nc2nc(-c3ccccc3)cs2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.60
ELOVL1 Q9BW60 1/20 0.58
PARP1 P09874 1/20 0.57
MAPT P10636 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
GAA P10253 1/20 0.56
PHGDH O43175 3/20 0.56
ADORA3 P0DMS8 1/20 0.56
USP2 O75604 1/20 0.54
ALDH1A1 P00352 1/20 0.54
PKM P14618 1/20 0.54
ALOX15 P16050 1/20 0.54
MAPK1 P28482 1/20 0.54
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22971633 0.90 ALOX5 (0.55) SCDELOVL1MAPTMEN1KMT2A
SCHEMBL21241936 0.89 HDAC3 (0.50) SCDELOVL1MAPTMEN1KMT2A
SCHEMBL22971654 0.87 ABL1 (0.55) SCDMAPTHDAC3HDAC4HDAC1
SCHEMBL22971635 0.87 ROCK1 (0.56) PARP1MAPTALDH1A1HDAC3HDAC4
SCHEMBL22971639 0.86 RAB9A (0.62) MAPTMEN1KMT2AADORA3ALDH1A1
SCHEMBL22971693 0.86 GSTO1 (0.53) SCDMAPTMEN1KMT2AUSP2
SCHEMBL22971735 0.86 HDAC1 (0.56) MAPTMEN1KMT2AGAAPHGDH
SCHEMBL22971678 0.86 HDAC3 (0.49) SCDMEN1KMT2AHDAC3HDAC4
SCHEMBL22971707 0.85 ROCK1 (0.54) PARP1
SCHEMBL22971553 0.85 ROCK1 (0.54) SCDELOVL1PARP1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SCD 3594/4885ELOVL1 2017/4885PARP1 491/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SCD 3594/4885ELOVL1 2017/4885PARP1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.